Drug Delivery in Retinoblastoma.

Abstract

Retinoblastoma is considered a prototype pediatric malignancy as retinoblastoma research has been instrumental in advancing our knowledge of cancer genetics, tumor suppressor genes, and the development of new treatment approaches. Also, retinoblastoma boasts one of the highest survival rates among pediatric cancers, with survival rates often exceeding 90% in developed countries. The research focus is shifting towards improved globe and vision salvage. Also, there is emphasis on advancing treatments that are tailored based on individual patient characteristics, including tumor genetics and molecular markers, to improve outcomes and minimize side effects.